The evaluation of cognitive function in the dementias: Methodological and regulatory considerations

Dialogues in Clinical Neuroscience

Volumn 5, Issue 1, 2003, Pages 77-88

  Wesnes, Keith A ^a,b   Harrison, John E ^c  

^a Cognitive Drug Research Ltd ^*  (United Kingdom)

^b NORTHUMBRIA UNIVERSITY   (United Kingdom)

^c Cambridge Psychometric Consultants   (United Kingdom)

Author keywords

Alzheimer's disease; Automated testing; Cognitive function; Cognitive testing; Dementia; Dementia with Lewy bodies

Indexed keywords

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSECTION; ARTICLE; CAREGIVER; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEMENTIA; DIAGNOSTIC TEST; DIFFUSE LEWY BODY DISEASE; HUMAN; MEMORY DISORDER; ONSET AGE; OUTCOMES RESEARCH;

EID: 0038417444     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res. 1975;12:189-198.
3. Swainson R, Hodges JR, Galton CJ, et al. Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks. Dement Geriatr Cognitive Disord. 2001;12:265-280.
4. Veroff AE, Cutler NR, Sramek JJ, Prior PL, Mickelson W, Hartman JK. A new assessment tool for neuropsychological research: the computerised neuropsychological test battery. J Geriatr Psychiatry Neurol. 1991;4:211-217.
5. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GR. The Cognitive Drug Research computerised assessment system for demented patients: a validation study. Int J Geriatr Psychiatry. 1991;6:95-102.
6. Mohr E, Walker D, Randolph C, Sampson M, Mendis T. The utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia. Int Psychogeriatr. 1996;3:397-411.
7. Ferris S, Lucca U, Mohs R, et al. Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11 (suppl 3):34-38.
8. Wesnes KA, Hildebrand K, Mohr E. Computerised cognitive assessment. In: Wilcock GW, Bucks RS, Rocked K, eds. Diagnosis and Management of Dementia: A Manual for Memory Disorders Teams. Oxford, UK: Oxford University Press; 1999:124-136.
9. Nebes RD, Brady CB. Focussed and divided attention in Alzheimer's disease. Cortex. 1989;26:30S-315.
10. Baddeley AD, Baddeley HA, Bucks RS, Wilcock GK. Attentional control in Alzheimer's disease. Brain. 2001;124:1492-1508.
11. Foster JK. Selective attention in Alzheimer's disease. Front Biosci. 2001;6:135-153.
12. Perry RJ, Hodges JR. Attention and executive deficits in Alzheimer's disease. Brain. 1999;122:383-404.
13. Wesnes K, Warburton DM. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology. 1984;82:147-150.
14. Wesnes KA. The extent of the involvement of cholinergic deterioration in the profile of cognitive impairment seen in Alzheimer's disease. Proc Br Psychol Soc. 1996;4:93.
15. Wesnes KA. The pathology of attention of the dementias. J Psychopharmacol. 1996;10(suppl):A51.
16. Sahakian BJ, Owen AM, Morant NJ, et al. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology. 1993;110:395-401.
17. Wesnes K, Scott M, Boyle M, Surmon DJ, Wilcock GK. Use of the Cognitive Drug Research computerised assessment system to measure the efficacy of THA and galanthamine in Alzheimer's disease. Psychopharmacol Bull. 1994;30:139.
18. Siegfried KR. Pharmacodynamic and early clinical studies with velnacrine. Acta Neurol Scand Suppl. 1993;149:26-28.
19. Wesnes KA, Scott M, Morrison S, Greenwood D, Russell-Duff K, Wilcock GK. The effects of galanthamine on attention in Alzheimer's disease. J Psychopharmacol. 1998;12:(suppl A):A46.
20. Ayre G, Ballard C, Pincock C, McKeith I, Sahgal A, Wesnes KA. Double dissociation between dementia with Lewy bodies and Alzheimer's disease on tests of attentional and mnemonic function: the role of the basal fore-brain. J Psychopharmacol. 1998;12(suppl A):A41.
21. Walker MP, Ayre GA, Cummings JL, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease and vascular dementia. Neurology. 2000;54:1616-1625.
22. McKeith IG, Ayre GA. Consensus criteria for the clinical diagnosis of dementia with Lewy bodies. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisnieswski HM eds. Alzheimer's disease: Biology, Diagnosis and Therapeutics. Chichester, UK: John Wiley & Sons; 1997:167-178.
23. Ayre GA, McKeith IG, Sahgal A, Ballard CG, Wesnes KA. Dementia with Lewy bodies, Alzheimer's disease and vascular dementia show distinct patterns of cognitive impairment. J Psychopharmacol. 1997;11(suppl):A56.
24. Moon G, Wesnes KA, Manktelow TC. Cognitive deficits in recently diagnosed untreated patients with Parkinson's disease. J Psychopharmacol. 2002;16(suppl):A31.
25. Ballard C, Manktelow TC, Arsland D, Wesnes KA, Starrfelt R. Attention and fluctuating attention in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Psychopharmacol. 2002;16(suppl):A31.
26. Ballard C, Wesnes KA, O'Brien J, et al. Cognitive impairments in elderly stroke patients without dementia: profile and MRI correlates. J Psychopharmacol. 2002;16(suppl):A31.
27. Wesnes KA, Bullock R. The emerging importance of attention and the speed of cognitive function in ageing and dementia research. CPD Bull Old Age Psychiatry. 2001;3:11-15.
28. Nicholl CG, Lynch S, Kelly CA, et al. The Cognitive Drug Research computerised assessment system in the evaluation of early dementia - is speed of the essence? Int J Geriatr Psychiatry. 1995;10:199-206.
29. Harrison JE. Cognitive testing and drug development. Clin Res Focus. 2001;12:5-11.
30. Harrison JE. Routine cognitive testing for all drugs? Drug Discovery Today. 2002;7:101-102.
31. Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord. 1998;12:304-312.
32. Leber P. Guidelines for the Clinical Evaluation of Antidementia Drugs. Bethesda, Md: Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation Research; 1990.
33. McKeith IG, Del Ser T, Spano F, et al. Efficacy of rivastigmine in dementia with Lewy bodies: results of a randomised placebo-controlled international study. Lancet. 2000;356:2031-2036.
34. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology. 1996;47:1113-1124.
35. Cummings JL. Cholinesterase inhibitors: expanding applications. Lancet. 2000;356:2024-2025.
36. Wesnes K, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. Dement Geriatr Cognitive Disord. 2002;13:183-192.
37. Allain H, Neuman E, Malbezin M, et al. Bridging study of S12024 in 53 in-patients with Alzheimer's disease. J Am Geriatr Soc. 1997;45:125-126.
38. Templeton L, Barker A, Wesnes K, Wilkinson D. A double-blind, placebo-controlled trial of intravenous flumazenil in Alzheimer's disease. Hum Psychopharmacol. 1999;14:239-245.
39. NICE. Technology Guidance Appraisal No. 19: Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London, UK: National Institute for Clinical Excellence; 2001.